{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:23:07Z","timestamp":1788340987979,"version":"build-2803163510"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Study Design:<\/jats:title>\n                    <jats:p>Retrospective cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To investigate the relationship between GLP-1 receptor agonist exposure and incidence of vertebral fracture and surgical intervention for these injuries in patients with osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of Background Data:<\/jats:title>\n                    <jats:p>Vertebral fractures are relatively common in patients with osteoporosis and frequently result in substantial morbidity, such as persistent pain and functional deficit. Although primarily indicated for the management of type 2 diabetes mellitus and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated positive effects on bone mineral density (BMD) in the lumbar spine. However, it remains unknown if this effect translates to positive clinical outcomes for patients with osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study utilized the TriNetX database to identify female patients aged over 50 years diagnosed with osteoporosis without a current pathologic fracture within the 10-year period ended January 1, 2025. The study group included patients with a history of GLP-1 RA use after osteoporosis diagnosis compared with a control group with no GLP-1 RA exposure. Cohorts were propensity-matched based on baseline demographic characteristics, BMI, HbA1c, eGFR, medical comorbidities, osteoporotic medication use, and serum calcium, phosphate, and vitamin D levels. Primary outcomes included incidence of vertebral collapse and vertebral augmentation within the 10-year study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were 56,142 matched pairs. The rate of vertebral fracture in the experimental group was \u223c1.9% compared with 4.3% in the control group (RR: 0.434, 95% CI: 0.404\u20130.467,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). In addition, GLP-1 RA exposure was associated with a lower incidence of kyphoplasty or vertebroplasty (RR: 0.453, 95% CI: 0.381\u20130.538,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonist use is associated with a lower incidence of vertebral fracture and osteoporotic fracture intervention in female patients aged 50+ with osteoporosis. These findings underscore the potential protective effects of GLP-1 receptor agonists in patients with poor bone quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>Level III.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bsd.0000000000002145","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:01:30Z","timestamp":1788339690000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3878-5183","authenticated-orcid":false,"given":"Kyle","family":"Stump","sequence":"first","affiliation":[{"name":"Lewis Katz School of Medicine at Temple University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine at Temple University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Aynaszyan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Temple University Hospital, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ricci","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine at Temple University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Pazionis","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Temple University Hospital, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal osteoporosis","volume":"389","author":"Walker","year":"2023","journal-title":"N Engl J Med"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00198-025-07489-y","article-title":"Prevalence and incidence of osteoporotic vertebral fractures in community-dwelling European older adults: an observational analysis of the DO-HEALTH trial","volume":"36","author":"Albrecht","year":"2025","journal-title":"Osteoporos Int"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00198-017-3909-3","article-title":"Worldwide prevalence and incidence of osteoporotic vertebral fractures","volume":"28","author":"Ballane","year":"2017","journal-title":"Osteoporos Int"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"e0291561","DOI":"10.1371\/journal.pone.0291561","article-title":"Mortality risk after the first occurrence of osteoporotic vertebral compression fractures in the general population: a nationwide cohort study","volume":"18","author":"Son","year":"2023","journal-title":"PLoS One"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41598-023-50145-w","article-title":"Prevalence, incidence of and risk factors for vertebral fracture in the community: the Vietnam Osteoporosis Study","volume":"14","author":"Nguyen","year":"2024","journal-title":"Sci Rep"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00402-011-1355-9","article-title":"Biomechanics of vertebral compression fractures and clinical application","volume":"131","author":"Adams","year":"2011","journal-title":"Arch Orthop Trauma Surg"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11914-010-0031-2","article-title":"Biomechanics of vertebral fractures and the vertebral fracture cascade","volume":"8","author":"Christiansen","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00198-006-0304-x","article-title":"The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis","volume":"18","author":"Briggs","year":"2007","journal-title":"Osteoporos Int"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5435\/00124635-201103000-00007","article-title":"The treatment of symptomatic osteoporotic spinal compression fractures","volume":"19","author":"Esses","year":"2011","journal-title":"J Am Acad Orthop Surg"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3174\/ajnr.A5458","article-title":"Vertebroplasty and kyphoplasty for osteoporotic vertebral fractures: what are the latest data?","volume":"39","author":"Chandra","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s00198-011-1639-5","article-title":"Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures","volume":"22","author":"Boonen","year":"2011","journal-title":"Osteoporos Int"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"22404","DOI":"10.1038\/s41598-024-74463-9","article-title":"Prevalence of vertebral fractures and associated factors in Thai diabetic postmenopausal women","volume":"14","author":"Samakkarnthai","year":"2024","journal-title":"Sci Rep"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00264-016-3146-y","article-title":"Increased risk of vertebral fracture in patients with diabetes: a meta-analysis of cohort studies","volume":"40","author":"Wang","year":"2016","journal-title":"Int Orthop"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1530\/EJE-20-0507","article-title":"Metformin use is associated with a lower risk of osteoporosis\/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus","volume":"184","author":"Tseng","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"3361309","DOI":"10.1155\/2021\/3361309","article-title":"Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study","volume":"2021","author":"Cai","year":"2021","journal-title":"Biomed Res Int"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"1785321","DOI":"10.1155\/2024\/1785321","article-title":"Effects of glucagon-like peptide-1 receptor agonists on bone metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"2024","author":"Li","year":"2024","journal-title":"Int J Endocrinol"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"117338","DOI":"10.1016\/j.bone.2024.117338","article-title":"Association of glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"192","author":"Zhang","year":"2025","journal-title":"Bone"},{"key":"R21-20260902","doi-asserted-by":"crossref","first-page":"825417","DOI":"10.3389\/fphar.2022.825417","article-title":"Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks","volume":"13","author":"Chai","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"R22-20260902","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.spinee.2025.07.010","article-title":"Association between glucagon-like peptide-1 receptor agonists and non-fusion risk after single-level anterior cervical discectomy and fusion","volume":"26","author":"Chang","year":"2026","journal-title":"Spine J"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1227\/neu.0000000000003291","article-title":"Perioperative glucagon-like peptide-1 agonist use and rates of pseudarthrosis after single-level lumbar fusion: a large retrospective cohort study","volume":"97","author":"Agrawal","year":"2024","journal-title":"Neurosurgery"},{"key":"R25-20260902","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R26-20260902","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","article-title":"Screening for osteoporosis: US preventive services task force recommendation statement","volume":"154","year":"2011","journal-title":"Ann Intern Med"},{"key":"R27-20260902","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s11999-010-1279-7","article-title":"Comparison of 5766 vertebral compression fractures treated with or without kyphoplasty","volume":"468","author":"Zampini","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"R28-20260902","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"R29-20260902","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989","volume":"7","author":"Cooper","year":"1992","journal-title":"J Bone Miner Res"},{"key":"R30-20260902","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s001980170015","article-title":"3rd. Impact of hip and vertebral fractures on quality-adjusted life years","volume":"12","author":"Tosteson","year":"2001","journal-title":"Osteoporos Int"},{"key":"R31-20260902","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2106\/JBJS.G.00675","article-title":"Mortality following the diagnosis of a vertebral compression fracture in the Medicare population","volume":"90","author":"Lau","year":"2008","journal-title":"J Bone Joint Surg Am"},{"key":"R32-20260902","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1001\/jama.298.23.2761","article-title":"Long-term risk of incident vertebral fractures","volume":"298","author":"Cauley","year":"2007","journal-title":"JAMA"},{"key":"R33-20260902","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jbmr.3595","article-title":"Adding lateral spine imaging for vertebral fractures to densitometric screening: improving ascertainment of patients at high risk of incident osteoporotic fractures","volume":"34","author":"Prince","year":"2019","journal-title":"J Bone Miner Res"},{"key":"R34-20260902","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/obr.12885","article-title":"The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: systematic review and meta-analysis of observational studies","volume":"20","author":"Hidayat","year":"2019","journal-title":"Obes Rev"},{"key":"R35-20260902","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00198-016-3595-6","article-title":"Risk of fractures and diabetes medications: a nationwide cohort study","volume":"27","author":"Choi","year":"2016","journal-title":"Osteoporos Int"},{"key":"R36-20260902","doi-asserted-by":"crossref","first-page":"861422","DOI":"10.3389\/fendo.2022.861422","article-title":"SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study","volume":"13","author":"Al-Mashhadi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R37-20260902","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00592-025-02468-5","article-title":"Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis","volume":"62","author":"Tan","year":"2025","journal-title":"Acta Diabetol"},{"key":"R38-20260902","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jcp.22243","article-title":"Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor","volume":"225","author":"Nuche-Berenguer","year":"2010","journal-title":"J Cell Physiol"},{"key":"R39-20260902","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fendo.2017.00098","article-title":"The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R40-20260902","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/met.2014.0074","article-title":"Relationships among the metabolic syndrome, bone mineral density, bone turnover markers, and hyperglycemia","volume":"13","author":"Terzi","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"R41-20260902","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of Glp-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"Ros-Madrid","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"key":"R42-20260902","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1038\/s41598-024-65571-7","article-title":"Correlation between bone mineral density and type 2 diabetes mellitus in elderly men and postmenopausal women","volume":"14","author":"Luo","year":"2024","journal-title":"Sci Rep"},{"key":"R43-20260902","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2016-2569","article-title":"Longer duration of diabetes strongly impacts fracture risk assessment: The Manitoba BMD Cohort","volume":"101","author":"Majumdar","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20260902","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/BRS.0000000000005099","article-title":"No difference in short-term surgical outcomes from semaglutide treatment for type 2 diabetes mellitus after cervical decompression and fusion: a propensity score-matched analysis","volume":"50","author":"Tao","year":"2025","journal-title":"Spine (Phila Pa 1976)"},{"issue":"12","key":"R45-20260902","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"23","author":"Kindel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Spine Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BSD.0000000000002145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:01:35Z","timestamp":1788339695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BSD.0000000000002145"}},"subtitle":["A Propensity-Matched Analysis"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1097\/bsd.0000000000002145","relation":{},"ISSN":["2380-0186","2380-0194"],"issn-type":[{"value":"2380-0186","type":"print"},{"value":"2380-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2025-10-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}